A Phase 3 interventional study of 5-fluorouracil/salicylic acid and Vehicle in Actinic Keratosis, sponsored by Almirall, S.A.. Completed at 14 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-08-05.
Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fluorouracil in Keratosis, Actinic — 3 open to participants now, 5 under way, 1 of them phase 3. Fluorouracil · Keratosis, Actinic.
Among the 19 studies testing fluorouracil in Keratosis, Actinic, this one is the 7th largest by enrollment, is one of 3 that started in 2014, is one of 9 in phase 3, and was the 10th registered.
343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.
Browse Keratosis, Actinic studies →3 of the 19 studies testing fluorouracil in Keratosis, Actinic are open now, in 1 country. Recruiting first, the newest first:
West Virginia University · Sites in United States
Ages 18–50
University of California, Davis · Sites in United States
Ages 18+
St Vincent's University Hospital, Ireland
Ages 18+
By country, each count listing its studies:
Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →
Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 9 · Phase 4 4
First in 2003; this study’s year is marked. 3 started in 2014.
This study's enrollment of 166 is above the median of 60 across 295 interventional studies indexed under Keratosis, Actinic.
Median enrollment 60 across the 19 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 19 have an industry lead sponsor. The 10 most frequent:
Almirall, S.A. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
14 studies in Keratosis, Actinic by Almirall, S.A.: none open now, 1 under way, none of them phase 3. Of 13 finished, 7 (54%) have results posted.
Among the 14 studies in Keratosis, Actinic by Almirall, S.A., this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2014, is one of 7 in phase 3, and was the 5th registered.
Almirall, S.A.’s Keratosis, Actinic studies by the year they started, since 2008.
2 of the studies testing fluorouracil in Keratosis, Actinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05699603University of ArizonaTesting the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients | 2027-02-01 |
| NCT07401277West Virginia UniversityActinic Keratoses Treated With 5-fluorouracil Plus Aluminum | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies testing fluorouracil in Keratosis, Actinic, from their registry updates:
Among Almirall, S.A.’s 14 in Keratosis, Actinic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this vehicle-controlled study is to determine the efficacy and safety of a solution of Actikerall® (containing 5-fluorouracil 0.5% and salicylic acid 10.0%) in the field-directed treatment of grade I-II actinic keratosis, when it is applied to the affected area once daily for 12 weeks.
A secondary objective of this study is to evaluate the efficacy of Actikerall® solution on subclinical actinic keratosis lesions in a subset of patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Actikerall® solution (5-fluorouracil 0.5%, salicylic acid 10.0%) applied to the affected area once-daily for 12 weeks
Drug: 5-fluorouracil/salicylic acid
Vehicle solution applied to the affected area once-daily for 12 weeks
Drug: Vehicle
Drug pages: Fluorouracil · Salicylic Acid
Also known as: Actikerall
Percentage of patients with complete clinical clearance of actinic keratosis lesions in the treatment field
Complete Clinical Clearance is defined as no clinically visible actinic keratosis lesions in the selected treatment area
Time frame: Week 20
Percentage of patients with partial clinical clearance of actinic keratosis lesions in the treatment field
Partial clearance is defined as a 75% or greater reduction in the number of clinically visible actinic keratosis lesions in the selected treatment area
Time frame: Week 20
Percentage change from baseline in the total number of actinic keratosis lesions
Time frame: Week 20
Global assessment of efficacy by the physician (Physician Global Assessment)
Time frame: Week 20
Change from baseline in total score of the Dermatology Life Quality Index (DLQI)
Time frame: Week 20
Total score of the patients´ treatment satisfaction questionnaire for medication (TSQM)
Time frame: Week 20
Percentage of patients with complete clearance of three pre-defined subclinical actinic keratosis lesions
Sub-clinical lesions will be determined using reflectance confocal microscopy in a subset of 30 patients
Time frame: Week 20
Percentage change from baseline in the three selected actinic keratosis subclinical lesions
Sub-clinical lesions will be determined using reflectance confocal microscopy in a subset of 30 patients
Time frame: Week 20
Percentage of patients for which the clearance of one pre-defined representative clinical actinic keratosis lesion is confirmed by reflectance confocal microscopy
Determined using reflectance confocal microscopy in a subset of 30 patients
Time frame: Week 20
The number of patients with adverse events
Time frame: Week 20
The record gives a start of Oct 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluorouracil · Salicylic Acid